Treatment of Metastatic Non-Adenoid Cystic Salivary Gland Carcinoma Eligible for Systemic Therapy

Clinical Scenario

This protocol addresses patients with non-adenoid cystic salivary gland carcinoma of the parotid gland who present with metastatic disease and are candidates for initiation of systemic therapy.

Treatment Approach

For patients with symptomatic metastatic disease, the protocol involves cytotoxic chemotherapy combinations. Several distinct combination regimens are addressed — the complete evidence-based algorithm is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1200/JCO.21.00449

For patients with nonadenoid cystic salivary gland cancer who are candidates for initiation of systemic therapy, targeted therapy based on tumor molecular alterations (ie, AR, HER2, and NTRK) may be offered if a clinical trial is not available.

Cytotoxic chemotherapy combinations may be offered to patients with symptomatic disease.

View source ↗